HIGHBuilt-inProduct / Revenue mix
Decipher Prostate and Afirma tests
“10-K Item 1A: 'Most of our revenue to date has been derived from sales of our Decipher Prostate and Afirma laboratory developed tests (LDTs)'”
VCYT · Concentration risk · 10-K extracted
Veracyte (VCYT) concentration risks
Updated
The most significant concentration Veracyte discloses is Decipher Prostate and Afirma tests, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Veracyte’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 4 disclosed concentrations
HIGH2
MEDIUM2
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHOutside partySupplier
sole suppliers for reagents and equipment
“10-K Item 1A: 'We rely on sole suppliers for some of the reagents, equipment, and other materials used to perform or develop our tests'”
MEDIUMBuilt-inCustomer
34%
Medicare Fee-For-Service
“10-K Item 1: 'Medicare Fee-For-Service accounted for 34%, 33% and 35% of our testing revenue'”
MEDIUMBuilt-inRegulatory
MolDX / Palmetto GBA
“10-K Item 1: 'Medicare coverage for most of Veracyte’s tests is determined through the MolDX program, administered by the MAC, Palmetto GBA'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-06-24The company's concentration profile spans product, supply, customer, and regulatory dimensions, making it one of the more layered disclosed profiles in the clinical diagnostics space. Most revenue to date has been derived from the Decipher Prostate and Afirma laboratory developed tests, a high-share structural concentration reflecting that the company's commercial infrastructure, payer contracts, and brand recognition are built around these two flagship tests. The structural character reflects a deliberate test-development strategy rather than over-reliance on a single buyer. The supply side introduces a high-share dependency: sole suppliers are relied upon for some of the reagents, equipment, and other materials used to perform or develop the tests. No alternate sourcing is disclosed for these critical inputs, making the supplier relationships the most idiosyncratic risk in the profile. On the revenue side, Medicare Fee-For-Service accounted for 34% of testing revenue in the most recent year, a medium-share structural exposure — government reimbursement is a structural feature of the diagnostic laboratory business model, and Medicare coverage policies directly set the accessible market. Reinforcing that regulatory dependency, coverage for most tests is determined through the MolDX program administered by Palmetto GBA, a medium-share structural exposure where a single Medicare Administrative Contractor effectively controls test coverage and pricing decisions for the majority of the product portfolio. Together the four exposures define a business where product breadth is limited, supply is partially sole-sourced, and the majority of revenue flows through a government reimbursement system whose terms are set by entities outside the company's control.
For the engine’s reasoning on VCYT’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Diagnostics & Research
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| VCYT● | Veracyte, Inc. | 2 | 2 | 0 | 4 |
| ADPT | Adaptive Biotechnologies Corpor | 2 | 0 | 0 | 2 |
| CRL | Charles River Laboratories Inte | 1 | 1 | 0 | 2 |
| BLLN | BillionToOne, Inc. | 1 | 0 | 0 | 1 |
| A | Agilent Technologies, Inc. | 0 | 1 | 0 | 1 |
| DGX | Quest Diagnostics Incorporated | 0 | 1 | 0 | 1 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.